Biomarkers of Alzheimer’s Disease: New Insights
Deadline for manuscript submissions: closed (10 April 2023) | Viewed by 23165
Interests: neuropathology; biomarkers of neurodegeneration
Special Issues, Collections and Topics in MDPI journals
Impaired cognitive function is a hallmark of Alzheimer’s disease (AD), and often one of the first symptoms. However, changes in cognitive function develop slowly over time and patients are diagnosed at an advanced stage of molecular pathology. The failure to diagnose AD, the most common form of dementia in the elderly, at an early stage of molecular pathology is considered to be the major reason why causative treatments have failed in clinical trials. Molecular biomarkers that could detect individuals at risk for developing AD and allow for timely intervention remain highly desirable. Cortical measurements of amyloid-beta and tau depositions via magnetic resonance imaging (MRI) and positron emission tomography (PET) are expensive and thus not accessible on the scale needed for a public health challenge such as AD. Large epidemiological studies provide a sufficient number of subjects to develop a robust classifier enabling the correlation of cognitive status in densely phenotyped individuals with molecular signatures obtained via systematic biobanking using reliable standard operating procedures. To that end, plasma P-tau217 levels in multiple international cohorts distinguished AD from other neurodegenerative diseases. Because the National Institute of Aging—Alzheimer’s Association research framework aims to define AD biologically, it also seeks to expand AD biomarkers according to the scientific progress in the field of AD pathogenesis.
Prof. Dr. Ivana Delalle
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- plasma AD biomarkers
- AD pathogenesis biomarkers
- biomarkers of cognitive decline
- biomarkers of neurodegeneration
- epigenetic dysregulation
- AD-risk genetic variants